Amazon Biotech Obtains Financing Of $250,000 For Phase II HIV Clinical Trials

Amazon Biotech, Inc. (OTCBB: AMZB) announced today that the company received $250,000 in funding for previously announced Phase II HIV clinical trials as well as an additional $350,000 in commitments for further funding.

MORE ON THIS TOPIC